Unknown

Dataset Information

0

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications.


ABSTRACT:

Background

Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM).

Methods

We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24?months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II.

Results

Median age was 44?years (IQR 36-53), median CD4+ cell count at nadir was 312 cells/mm3 (IQR 187-450). A total of 120 subjects (72.7%) were receiving successful antiretroviral therapy (ART). At baseline and follow-up, the frequency of HR-HPV was significantly higher in the anal site (65.4% vs 9.4 and 62.4% vs 6.8%, respectively). Only 2.9% of subjects were persistently HR-HPV negative at both sites. All oral HR-HPV were single at baseline vs 54.6% at baseline at the anal site (p?=?0.005), and all oral HR-HPV were single at follow-up vs 54.4% at anal site at follow-up (p?=?0.002). The lowest rate of concordance between the oral and anal results was found for HR-HPV detection; almost all HR-HPV positive results at both anal and oral sites had different HR-HPV.The most frequent HR-HPV in anal swabs at baseline and follow-up were HPV-16 and HPV-52.At follow-up at anal site, 37.5% of patients had different HR-HPV genotypes respect to baseline, 28.8% of subjects with 1 HR-HPV at baseline had an increased number of HR-HPV, and patients on ART showed a lower frequency of confirmed anal HR-HPV detection than untreated patients (p?=?0.03) over time. Additionally,54.6 and 50.5% of patients had only HR-vax-HPV at anal site at baseline and follow-up, respectively; 15.2% had only HR-vax-HPV at baseline and follow-up.

Conclusions

We believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.

SUBMITTER: Parisi SG 

PROVIDER: S-EPMC6537447 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4727320 | BioStudies
2019-01-01 | S-EPMC6894774 | BioStudies
2020-01-01 | S-EPMC7160926 | BioStudies
2012-01-01 | S-EPMC3431392 | BioStudies
2013-01-01 | S-EPMC4437419 | BioStudies
2018-01-01 | S-EPMC6033400 | BioStudies
2020-01-01 | S-EPMC7755021 | BioStudies
1000-01-01 | S-EPMC6103209 | BioStudies
2017-01-01 | S-EPMC5398673 | BioStudies
2020-01-01 | S-EPMC7510729 | BioStudies